Friday 7 May | |
Numis Corp PLC | Half Year Results |
International Consolidated Airlines Group SA | Q1 Results |
InterContinental Hotels Group PLC | Q1 Results |
Monday 10 May | |
HgCapital Trust PLC | Q1 Results |
Kosmos Energy Ltd | Q1 Results |
Provident Financial Group PLC | Full Year Results |
Smartspace Software PLC | Full Year Results |
Victrex PLC | Half Year Results |
Tuesday 11 May | |
Air Partner PLC | Full Year Results |
Angling Direct PLC | Full Year Results |
Arrow Global Group PLC | Q1 Results |
Coca-Cola European Partners PLC | Trading Statement |
Morgan Advanced Materials PLC | Trading Statement |
Treatt PLC | Half Year Results |
WM Morrison Supermarkets PLC | Q1 Results |
Zytronic PLC | Half Year Results |
Wednesday 12 May | |
TI Fluid Systems PLC | Trading Statement |
Tui AG | Half Year Results |
Compass Group PLC | Half Year Results |
Coca-Cola HBC AG | Trading Statement |
Mears Group PLC | Full Year Results |
Stock Spirits Group PLC | Half Year Results |
National Express Group PLC | Trading Statement |
Vertu Motors PLC | Full Year Results |
Airtel Africa PLC | Full Year Results |
Vaalco Energy Inc | Q1 Results |
Thursday 13 May | |
3i Group PLC | Full Year Results |
Beazley PLC | Trading Statement |
Brewin Dolphin Holdings PLC | Half Year Results |
BT Group PLC | Full Year Results |
Burberry Group PLC | Full Year Results |
ContourGlobal PLC | Trading Statement |
Countryside Properties PLC | Half Year Results |
e-Therapeutics PLC | Full Year Results |
Grainger PLC | Half Year Results |
Greggs PLC | Trading Statement |
Hargreaves Lansdown PLC | Trading Statement |
Titon Holdings PLC | Half Year Results |
TT Electronics PLC | Trading Statement |
Valeura Energy Inc | Q1 Results |
Copyright 2021 Alliance News Limited. All Rights Reserved. |
e-Therapeutics Trading Up As Brain Cancer Trial To Resume Recruitment
LONDON (Alliance News) - Shares in e-Therapeutics PLC were trading higher Thursday after it said that it had been cleared by the US Food and Drug administration to resume recruiting patients for its Phase Ia study of compound ETS2101 in brain cancer. The company had previously paused recrui
Read more